These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17892924)

  • 1. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Castaldi P; Treglia G; Perotti G; Gross MD; Al-Nahhas A; Rubello D
    Biomed Pharmacother; 2008 Mar; 62(3):139-46. PubMed ID: 17892924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma.
    Rufini V; Salvatori M; Garganese MC; Di Giuda D; Lodovica Maussier M; Troncone L
    Rays; 2000; 25(2):273-82. PubMed ID: 11370545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional nuclear medicine imaging of medullary thyroid cancer.
    Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D
    Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
    Rufini V; Salvatori M; Saletnich I; Valenza V; Maussier ML; Martino G; Corsello SM; Pantusa M; Casolo A; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role?
    Castellani MR; Seregni E; Maccauro M; Chiesa C; Aliberti G; Orunesu E; Bombardieri E
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):430-40. PubMed ID: 19088696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic value of SST-A octreotide alone or with adjuvant treatment in patients with advanced medullary thyroid carcinoma and positive (111)In-octreotide scan.
    Vainas I; Drimonitis A; Boudina M; Kaprara A; Iakovou I; Salem N; Koussis C
    Hell J Nucl Med; 2005; 8(1):43-7. PubMed ID: 15886753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PET in medullary thyroid carcinoma.
    Rufini V; Treglia G; Perotti G; Leccisotti L; Calcagni ML; Rubello D
    Minerva Endocrinol; 2008 Jun; 33(2):67-73. PubMed ID: 18388854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
    Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
    Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
    Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
    Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
    Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
    Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of neuroendocrine tumors.
    Rufini V; Calcagni ML; Baum RP
    Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Herskovic T; Hanley D; Markowitz A; Dunn R; Siegel J; Kamal T; Goldenberg DM
    J Clin Oncol; 1996 Apr; 14(4):1209-17. PubMed ID: 8648376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
    Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
    J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
    Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
    Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma.
    Hoefnagel CA; Delprat CC; Zanin D; van der Schoot JB
    Clin Nucl Med; 1988 Mar; 13(3):159-65. PubMed ID: 2838213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of radionuclide therapy in medullary thyroid cancer.
    Castellani MR; Alessi A; Savelli G; Bombardieri E
    Tumori; 2003; 89(5):560-2. PubMed ID: 14870787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.